ClinicalTrials.gg
RecruitingNCT07873645Updated Nov 5, 2026

Study of UBT37034 Injection

A Phase 1 interventional study of UBT37034 and Placebo in Overweight , Obesity, sponsored by The United Bio-Technology (Hengqin) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The United Bio-Technology (Hengqin) Co., Ltd. (part of The United Laboratories International Holdings Limited) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 5, 2026Now RecruitingFirst site in China+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 601 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Planned enrollment
413th of 503
40 · median 120
Started
2026
with 134 others
Phase 1
93 of 601
29 open now
Primary completion
2027-08
later than 180 of 280 live
Registered
580th of 601
by date

Among the 601 studies in Obesity with a site in China, this one is the 413th largest by planned enrollment of the 503 interventional ones that give a count, is one of 135 that started in 2026, is one of 93 in phase 1, reaches primary completion later than 180 of the 280 other live ones, and was the 580th registered.

Obesity

11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 601 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

215 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 601 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This is a study of UBT37034 for injection in participants who have obesity or are overweight. The main purpose is to learn more about the safety, tolerability, drug concentration, drug action and immune response of repeated UBT37034 administration. This is a single-center, randomized, double-blind, placebo-controlled study with multiple ascending doses. A total of 40 participants will be enrolled in 4 different dose groups. Participants will receive UBT37034 or placebo in an 8:2 random ratio with dose titration. The study will last up to 24 weeks and includes screening, treatment and safety follow-up periods.

03

Conditions studied

  • Overweight , Obesity

Browse trials for

Keywords

  • Overweight
  • Obesity
  • UBT37034
  • safety
  • tolerability
04

In context

Obesity Reclassified

11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's planned enrollment of 40 is below the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

The United Bio-Technology (Hengqin) Co., Ltd. is the lead sponsor of 13 studies on the registry; 10 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-55 years (inclusive) at the time of form (ICF) signing;
  • ≥24 kg/m² at screening; weight >60 kg (male) or >50 kg (female) at screening;
  • Self-reported ≥3 months of diet and exercise control before screening, with ≤5% weight change in the prior 3 months;
  • The participant (and partner) has no plan for pregnancy from screening until 6 months after study completion. The participant is willing to use study-specified . No sperm or egg donation is permitted within 6 months after study completion;
  • Fully understands the study and provides voluntary written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Suspected or confirmed to components of products similar to the product, or to any of the investigational product; or subjects with allergic diathesis (multiple drug and food allergies).
  • History of medication meeting any of the following criteria:

    1)Use of prescription drugs, over-the-counter drugs, vitamin products, or herbal medicines within 14 days prior to screening or within at least 5 half-lives (whichever is longer); stable fixed-dose antihypertensive or lipid-lowering medications that have been taken for at least 1 month and have no impact on glucose metabolism and body weight are permitted; 2) received vaccination within 1 month before screening or planned to receive vaccination during the study; 3) used weight-modifying medications within 3 months before screening, including but not limited to marketed or investigational anti-obesity agents (e.g., GLP-1 analogues, orlistat), agents with mechanism similar to neuropeptide Y receptor agonists, tricyclic antidepressants, psychotropic agents or sedatives (e.g., mirtazapine, paroxetine, olanzapine, valproic acid and its derivatives); 4) used antihyperglycemic drugs within 3 months before screening (including but not limited to metformin, SGLT2 inhibitors, thiazolidinediones [TZDs], etc.) or agents that may alter glucose metabolism (e.g., systemic , growth hormone).

  • History or evidence of any of the following conditions:

    1. Presence of clinically severe disease or abnormality within 1 year prior to screening (including but not limited to disorders of the neuropsychiatric, cardiovascular, respiratory, hematologic and lymphatic, immune, renal, hepatic, gastrointestinal, metabolic, skeletal systems, etc.), which, in the opinion of the investigator, may compromise the safety of the trial participant, assessment of efficacy, or subject compliance;
    2. Diagnosis of type 1, type 2 diabetes mellitus, or other types of diabetes mellitus (history of gestational diabetes mellitus excluded);
    3. Secondary obesity caused by diseases (including but not limited to elevated cortisol [e.g., Cushing syndrome], pituitary/hypothalamic injury, hypothyroidism, etc.) or medications (including but not limited to long-term glucocorticoid use, antidepressants, etc.);
    4. History of clinically significant cardiovascular and cerebrovascular diseases within 6 months prior to screening, defined as:

      1. Myocardial infarction (MI) or unstable angina;
      2. Cardiac-related surgery (including coronary artery bypass grafting, percutaneous coronary intervention);
      3. Congestive heart failure ( (NYHA) Class III-IV);
      4. Cerebrovascular accident (old lacunar infarction excluded), including but not limited to hemorrhagic or ischemic stroke, or ;
      5. Other cardiovascular and cerebrovascular diseases deemed unsuitable for participation in this trial as assessed by the investigator;
    5. Prior or current severe retinal or macular disease at screening (including but not limited to proliferative retinopathy, macular edema, retinal detachment, etc.) that requires urgent further treatment as judged by the investigator;
    6. History of severe hypoglycemia (hypoglycemia accompanied by severe cognitive impairment requiring other therapeutic interventions for recovery) or recurrent symptomatic hypoglycemia (≥2 episodes within 6 months);
    7. Gastrointestinal emptying disorders at screening (e.g., gastroparesis, pyloric obstruction, intestinal obstruction, etc.), gastrointestinal diseases assessed by the investigator to increase risks after study drug administration (e.g., severe active ulcer, inflammatory bowel disease, acute gastroenteritis, uncontrolled gastroesophageal reflux disease, etc.), or a history of major gastrointestinal surgery (excluding fully recovered procedures such as gastrointestinal polypectomy, appendectomy, cholecystectomy, etc., which are judged by the investigator not to affect trial safety);
    8. Prior history of depression, or a Patient Health Questionnaire-9 (PHQ-9) score ≥10 at screening, or history of severe psychiatric disorders (including but not limited to suicidal ideation, schizophrenia, bipolar disorder, etc.);
    9. Positive response to suicidal ideation Item 4 or Item 5, or any positive response to suicidal behavior-related questions on the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening;
    10. Major surgery, severe trauma, or severe infection within 1 month prior to screening, deemed unsuitable for this study by the investigator;
    11. Prior history of malignant neoplasm;12) Limb deformity or disability that prevents accurate measurement of height, weight, or other indicators.
  • Abnormal laboratory findings at screening meeting any of the following:

    1. (HbA1c) ≥6.5% or fasting venous glucose ≥7.0 mmol/L. If the participant's fasting glucose during screening is 6.1-6.9 mmol/L, an oral glucose tolerance test (OGTT) is required for confirmation; subjects with a 2-hour post-load glucose ≥11.1 mmol/L will be excluded;
    2. Hepatic or renal impairment: serum (ALT) and/or aspartate aminotransferase (AST) ≥2 × (ULN); serum total ≥1.5 × ULN; estimated (eGFR) \<90 mL·min-¹·1.73m-² (calculated using the CKD-EPI 2021 equation);
    3. Thyroid dysfunction that cannot be controlled with a stable drug dose (for ≥3 months), or clinically significant abnormalities in thyroid function tests at screening requiring initiation of treatment;
    4. Fasting triglycerides ≥5.6 mmol/L;
    5. Serum amylase and/or lipase >2.0 × ULN;
    6. (INR) greater than the upper limit of normal;
    7. \<100 g/L;
    8. Systolic blood pressure ≥160 mmHg or \<90 mmHg, or diastolic blood pressure ≥100 mmHg or \<60 mmHg;
    9. Clinically significant (ECG) abnormalities, such as:a) Second- or third-degree atrioventricular block;b) Long syndrome, or QT interval corrected using Fridericia's formula (QTcF) >450 ms;c) Wolff-Parkinson-White syndrome;d) Heart rate \<50 beats per minute (bpm) or >100 beats per minute (bpm);e) Other severe arrhythmias requiring treatment;
    10. Positive surface antigen, positive virus antibody, positive antibody, or positive syphilis antibody at screening;
    11. Clinically significant abnormalities identified on physical examination, laboratory tests, etc., who, in the investigator's judgment, may pose substantial risk to the trial participant or interfere with the evaluation of safety and pharmacokinetics (PK) results, rendering them unsuitable for participation in this trial.
  • Participation in other interventional clinical trials within 3 months prior to screening (excluding those who only completed screening without randomization/enrollment, or those enrolled but did not receive study treatment);
  • Blood loss ≥400 mL (including trauma, blood sampling, blood donation) within 3 months prior to screening, or received transfusion of blood or blood components;
  • History of substance abuse, or positive urine drug screening;
  • Smoked more than 5 cigarettes or equivalent tobacco products per day within 3 months prior to screening, or unable to abstain from smoking during the trial;
  • Female subjects consuming >7 standard drinks per week or male subjects consuming >14 standard drinks per week within 28 days prior to screening (1 standard drink = 150 mL wine = 360 mL beer = 45 mL spirits), or consumed any alcohol-containing products within 48 hours before dosing, or had a positive breath alcohol test at the baseline visit, or unable to abstain from alcohol during the trial;
  • Consumed excessive amounts of tea, coffee or caffeine-containing beverages (>8 cups per day; 1 cup = 200 mL) within 14 days prior to screening, or consumed grapefruit, pomelo, or xanthine-rich foods/beverages; or unable to discontinue consumption of xanthine-rich foods or beverages (e.g., chocolate, tea, coffee, cola, etc.), grapefruit, pomelo, and products containing grapefruit or pomelo components (grapefruit juice, pomelo juice, etc.) from 48 hours prior to the first dose and throughout the trial period;
  • Female subjects who are breastfeeding or pregnant;
  • Intolerant to venipuncture, or with a history of vasovagal syncope triggered by needles or blood exposure;
  • Unable to maintain regular diet and exercise during the trial, or other conditions deemed by the investigator to render the subject unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    UBT37034 Dose 1

    Participants will receive UBT37034 subcutaneously (SC).

    Drug: UBT37034

  • Experimental
    UBT37034 Dose 2

    Participants will receive UBT37034 subcutaneously (SC).

    Drug: UBT37034

  • Experimental
    UBT37034 Dose 3

    Participants will receive UBT37034 subcutaneously (SC).

    Drug: UBT37034

  • Experimental
    UBT37034 Dose 4

    Participants will receive UBT37034 subcutaneously (SC).

    Drug: UBT37034

  • Placebo comparator
    Placebo

    Participants will receive placebo.

    Drug: Placebo

Interventions

  • DrugUBT37034

    Administered SC

  • DrugPlacebo

    Administered SC

07

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: Baseline to Week23

  2. Change from baseline in physical examinations

    Time frame: Baseline to Week 23

  3. Change from baseline in body temperature

    Time frame: Baseline to Week 23

  4. Change from baseline in pulse rate

    Time frame: Baseline to Week 23

  5. Change from baseline in blood pressure

    including systolic blood pressure and diastolic blood pressure

    Time frame: Baseline to Week 23

  6. Change from baseline in ECG QTcF interval

    Time frame: Baseline to Week 23

  7. Change from baseline in ECG RR interval

    Time frame: Baseline to Week 23

  8. Change from baseline in ECG heart rate

    Time frame: Baseline to Week 23

  9. Change from baseline in PHQ-9 total score

    Time frame: Baseline to Week 23

  10. Change from baseline in C-SSRS score

    Time frame: Baseline to Week 23

Secondary outcomes

  1. Cmax

    Time frame: Baseline to Week 23

  2. Tmax

    Time frame: Baseline to Week 23

  3. AUC0-t

    Time frame: Baseline to Week23

  4. AUC0-τ

    Time frame: Baseline to Week 23

  5. Change from baseline in body weight

    Time frame: Baseline to Week 23

  6. Change from baseline in Body Mass Index (BMI)

    Time frame: Baseline to Week 23

  7. Change from baseline in Waist Circumference (WC)

    Time frame: Baseline to Week 23

  8. Change from baseline in Waist-to-Hip Ratio (WHR)

    Time frame: Baseline to Week 23

  9. Change from baseline in Glycated Hemoglobin (HbA1c)

    Time frame: Baseline to Day 92

  10. Positive rate of anti-UBT37034 antibodies

    Time frame: Baseline to Week 23

  11. Antibody titer levels in anti-UBT37034 antibody-positive participants

    Time frame: Baseline to Week 23

  12. Positive rate of neutralizing antibodies (if applicable)

    Time frame: Baseline to Week 23

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Aug 2027, 10 months after the start.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 10 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Oct 14, 2026
StartActual
Oct 15, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
1 site added — first site in China
Show site
  • The Third Xiangya Hospital of Central South University · Changsha, China
Nov 5, 2026
Registered
First appeared on the registry
Oct 14, 2026
Show all 2 updates
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • The Third Xiangya Hospital of Central South University · Changsha, China
    + 1 other change: date precision
  2. Oct 14, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07873645
Responsible party
Sponsor
First posted
Oct 14, 2026
Start date
Oct 15, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Guoping Yang
Contact
ygp9880@163.com
+86-13974817168

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion